KNOXVILLE, Tenn., August 2, 2004 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT - News) announced today that AmerisourceBergen will sell the company's first over-the-counter (OTC) product, Pure-ific(TM) Antibacterial Hand Spray.
Pure-ific, which comes in a 1-ounce can, immediately kills up to 99.9 percent of germs on skin and prevents re-growth for up to six hours. Packaged as a quick-drying spray, Pure-ific is useful for mothers, travelers, and anyone else concerned about the spread of germs. Unlike most gel sanitizers, Pure-ific Antibacterial Hand Spray leaves no sticky residue and is appropriate both for hands and for hard surfaces, such as toilet seats.
AmerisourceBergen services the Good Neighbor Pharmacy Network and the Family Pharmacy Network. "Through our relationship with AmerisourceBergen, we hope to grow sales throughout the 2,000-member Good Neighbor Pharmacy Network, and then expand into the 2,500-store Family Pharmacy Network, as well," said Timothy C. Scott, Ph.D., Provectus president.
Scott said the AmerisourceBergen agreement is significant to Provectus for two reasons. "First, this agreement will launch our Pure-ific(TM) sales program into the private pharmacies market," Scott said. "Second, the revenues generated through Pure-ific sales will minimize our need for additional external funding to support our core work -- clinical trials in oncology and dermatology. That has always been a vital part of our corporate strategic plan to maximize shareholder value."
Provectus Pharmaceuticals Inc. licenses and sells products in three sectors of the health-care industry:
1) prescription medications and treatments, 2) medical devices, and 3) over-the-counter (OTC) pharmaceuticals,
such as Pure-ific(TM). Prescription drug products and devices address several
forms of difficult-to-treat cancers as well as diseases of the skin. OTC products address complementary markets,
primarily those involving skin care and comfort.
The Company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A Knoxville, TN 37931; telephone: 865/769-4011. For more information, contact the company at email@example.com or visit the corporate Web site: www.pvct.com.
This release and others statements issued or made from time to time by the company or its representatives contain statements that may constitute forward- looking statements. Those statements include statements regarding the intent, belief or current expectations of the company and members of its management teams as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.
For further information please contact: Craig Dees, CEO of Provectus Pharmaceuticals, Inc., +1-865-769-4011; or Media, Hilary Kaye, firstname.lastname@example.org, or Eve Gumpel, email@example.com, both of Hilary Kaye Associates, +1-714-426-0444, for Provectus Pharmaceuticals, Inc.
Legal Notice ©2002-2014 Provectus Biopharmaceuticals, Inc.